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**Value of the data**•The relationship between baseline and study characteristics and the variability of cIMT change in statin cIMT trials over time has not been well-studied.•These data show time-related trends in baseline and study characteristics that may influence the variability of mean mean and mean max cIMT results in statin clinical trials.•Statin cIMT trials conducted before 2000 had greater cIMT baseline values, LDL-C reduction and annualized cIMT changes than studies after 2000.•These trends are consistent with increased statin treatment and management of LDL-C lowering over recent years, bringing into question the utility of cIMT as a surrogate marker in clinical trials given the high standard of background statin therapy.•These results highlight the need to consider such factors in the design of future cIMT trials.

1. Data {#s0005}
=======

The predictive power of cIMT as a surrogate marker for the assessment of CVD risk reduction in lipid-lowering trials may be limited in some settings due to differences in study design, cIMT methods, and patient characteristics [@bib2], [@bib3], [@bib4]. With increased use of lipid-lowering therapy over recent years, it is possible that patient characteristics and study designs of cIMT trials have also changed in a manner which could influence the utility of cIMT in assessing LLT treatment effects. This analysis was undertaken to better understand how baseline factors and study characteristics may influence the variability of cIMT changes in intervention trials.

A summary of the cIMT trials included in the analyses reported in the original article [@bib1] and in this brief report are summarized in [Table 1](#t0005){ref-type="table"}. All 8 of the studies that were conducted before year 2000 were significantly positive for cIMT change, and the patients in those trials did not receive prior lipid-lowering therapy. However, the 9 studies conducted after 2000 were more variable for cIMT changes with 6 of these not showing significant cIMT change, the majority of which (4 of 6 trials) included patients that had received prior lipid-lowering therapy. The baseline mean mean and mean maximum cIMT and LDL-C levels were also generally greater for those studies conducted before 2000 than after 2000. The durations of the trials were also longer (≥2 years) in those conducted before 2000.

[Table 2](#t0010){ref-type="table"} summarizes the mean maximum baseline CCA/cIMT level and annualized changes for the overall studies (1988--2006) and those conducted before and after 2000, as well as for various study populations. For the overall studies combined (1988--2006), the baseline mean maximum CCA/cIMT level was 1.0866 mm and the annualized rate of change for the mean maximum CCA/cIMT from baseline was −0.0023 mm/yr (95% CI: −0.0050, −0004), indicating a statistically significant annualized change in cIMT. Baseline mean maximum cIMT levels were higher in populations of studies conducted before 2000 (1.2550 mm) than after 2000 (1.0181 mm), as well as in study populations of patients with CHD risk versus those without, and in those studies with greater LDL-C reductions, and those with thickened baseline cIMT. Annualized rates of change in maximum CCA/cIMT levels were also larger for the combined study populations conducted before year 2000 (−0.0134 mm/yr) than after 2000 (−0.0083 mm/yr), and for those studies in which patients had thickened baseline cIMT at study entry and also those which showed greater LDL-C reductions.

The baseline mean CCA/cIMT and annualized changes observed in pooled studies conducted before and after 2000 for various prespecified subgroups of interest are displayed in [Table 3](#t0015){ref-type="table"}. Consistent with the findings in the overall analysis cohort, baseline cIMT levels and annualized change for mean CCA/cIMT were generally greater in all subgroups assessed for the combined studies conducted before 2000 than after 2000. Similarly, mean max CCA/cIMT and annualized change in studies were also generally greater in all subgroups assessed in studies conducted before 2000 than after 2000 ([Table 4](#t0020){ref-type="table"}).

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Study design {#s0015}
-----------------

This was an exploratory analysis of study-level data from statin treatment arms of published cIMT imaging trials, as previously described in the original study article [@bib1]. [Fig. 1](#f0005){ref-type="fig"} displays the method of trial selection for the analysis. Following a detailed review of cIMT trials in the literature, 24 statin trials were identified that had both baseline- and study-end measurements for mean of the mean CCA/cIMT (mean of all mean measurements on CCA or a single mean cIMT value when not available), and/or mean of the maximum CCA/cIMT (mean of all maximum mean measurements on CCA, or single maximum mean or bulb values when not available). Of these, 7 trials were excluded due to insufficient data or mixed lipid-lowering therapy in the statin arm, and 17 studies conducted during 1988--2006 were selected on the basis of having at least one statin monotherapy arm in the absence of mixed therapy, baseline- and study-end values for mean of the mean and mean of the maximum CCA/cIMT. The selected studies included a mix of placebo (ACAPS, ARBITER II, BCAPS, CAIUS, CAPTIVATE, CASHMERE, KAPS, LIPID, METEOR, PLAC II, REGRESS) and active-controlled (ARBITER I, ASAP, RADIANCE I, RADIANCE II, ENHANCE, VYCTOR) studies ([Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}) [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21]. There were 13 trials with mean mean CCA/cIMT as the primary endpoint and 12 with mean maximum CCA/cIMT endpoints; these were assessed in 2 separate, but similar analyses.

2.2. Data extraction and analysis {#s0020}
---------------------------------

Only aggregate data in the published literature were collected from the studies. Demographic information (e.g., age and gender), study characteristics (study dates, CHD risk, heterozygous familial hypercholesterolemia \[FH\], baseline LDL-C, HDL-C and TG levels), and baseline- and study-end measurements for mean mean CCA/cIMT and mean max CCA/cIMT, and variability estimates were extracted from the publications. Baseline means of the mean CCA/cIMT and maximum CCA/cIMT levels were summarized for the overall population of studies, those conducted before and after 2000 (the median of enrollment dates for all studies), and studies that enrolled patients based on CHD risk, heterozygous FH, and thickened baseline cIMT. Subgroups of patients categorized by LDL-C reduction, age and gender were also assessed. Dichotomized variables for the subgroups were prespecified based on median values for the combined studies.

Studies were combined using a meta-analytic approach. The 13 trials included in the mean mean CCA/cIMT analysis were: ARBITER I, REGRESS, ASAP, KAPS, LIPID, METEOR, BCAPS, CASHMERE, CAPTIVATE, ENHANCE (simvastatin), ARBITER II (placebo), and Radiance I & II (atorvastatin). The 12 studies included in the analysis of mean maximum CCA/cIMT were: ACAPS, ARBITER I, BCAPS, CAIUS, CAPTIVATE, ENHANCE (simvastatin), REGRESS, METEOR, PLAC II, VYCTOR, and RADIANCE I & II (atorvastatin).

Study-end values were reported as a change from baseline in primary variables (mean mean or mean max CCA/cIMT) indicating regression and/or progression of cIMT. Annualized rates of change (regression and/or progression) were extracted as treatment differences for placebo-controlled studies and as change from baseline in each individual treatment arm for active-control studies. For active-controlled studies with 2 or more monotherapy arms, each treatment arm was included in the analysis as a separate data point. For trials in which annualized rates of change was not provided, it was calculated by dividing the reported change in cIMT by the duration of the study in years.

Estimates of variance for the baseline and study-end values for mean mean and mean max cIMT were extracted from the publications. In most cases the standard deviation was reported for baseline values and the standard error (SE) was reported for study-end values. In some instances the SE was not reported, and it was calculated from the reported 95% CIs or *p*-values for the treatment difference (placebo-controlled) or change from baseline (monotherapy arms) in cIMT. The rate of cIMT change was standardized (annualized) for this analysis; however, the SE reported in the publication was used regardless of study duration. An overall pooled estimate for the baseline CCA/ cIMT value and annualized rate of cIMT change was calculated by weighting each individual study by the inverse of the square of its standard error which was extracted from the publications. This resulted in studies with small variability having more weight in the pooled values than studies with large variability. Overall pooled estimates for the baseline CCA/cIMT value and annualized rate of change for mean of mean CCA and mean of max cIMT, were calculated using a fixed-effects model, by weighting each individual study by the inverse of the square of its standard error; thus, studies with small variability had more weight in the pooled values than studies with large variability.
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###### 

Summary of the included trials.

Table 1

  **Study (Reference)**                                **Treatment (mg)**[⁎⁎⁎](#tblt0005-fn1){ref-type="table-fn"}   **Age (yr)**                              **Female (%)**   **Population**   **Prior treatment**                                                                                                       **Study length (yr)**                                                      **Study (yr)**   **Baseline IMT thickness (mm)**   **Baseline mg/dl (mmol/l)**                                                              
  ---------------------------------------------------- ------------------------------------------------------------- ----------------------------------------- ---------------- ---------------- ------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------- --------------------------------- ----------------------------- ------------------------------- ------------ ------------- ------------
  **Statin studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ACAPS[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}        **L20-40**                                                    231                                       62               49               Asymptomatic CAD; LDL-C 60--90th percentiles; IMT≥1.5 - \<3.5 mm                                                          No prior LLT for 1 yr                                                      3                1989--1990                        *L***±***W*=1.15              *L***±***W*=1.33                155          45.8 (1.19)   140 (1.58)
  [@bib9]                                              Pbo=1.14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Pbo=1.32                                             (4.01)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Pbo                                                  230                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ARBITER I[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}    **P40**                                                       70                                        60               29               Adults (\>18 yr), ATPII lipid-lowering criteria                                                                           No prior LLT                                                               1                1999--2001                        *P*=0.615 *A*=0.625           *P*=0.808 *A*=0.935             152          49            207 (2.34)
  **A80**                                              68                                                            (3.94)                                    (1.27)                                                                                                                                                                                                                                                                                                                                                                             
  [@bib20]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ASAP[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}         **A80**                                                       160 163                                   48               61               hFH;                                                                                                                      Untreated or treated ≤1 yr, LDL-C \>173 mg/dL (4.48 mmol/l)                2                1997--1998                        *A*=0.86 *S*=0.87             NA                              315 (8.16)   46 (1.19)     165 (1.86)
  [@bib19]                                             **S40**                                                       mean CCA ≥0.7 mm and/or ≥0.9 mm in bulb                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  BCAPS[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}        Met                                                           200                                       61.8             54.5             Asymptomatic plaque (focal IMT \>1.2 mm) in right coronary artery                                                         No beta blocker or statin                                                  3                1991--1994                        Met=0.92 *F*=0.886            Bulb:                           158 (4.09)   53.2 (1.38)   104 (1.18)
  [@bib10]                                             Met=1.936 *F*=1.893                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                       Pbo=0.898                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  **F40**                                              200                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Pbo=1.875                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Pbo                                                  200                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  CAIUS[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}        **P40**                                                       151                                       55               47               Moderate HC, LDL-C 150--250 mg/dL (3.88--6.47 mmol/l), ≥1 cIMT lesion 1.3--3.5 mm                                         No prior LLT                                                               ≤3 yr            1991--1995                        NA                            *P*=1.06                        181 (4.69)   52.5 (1.36)   138 (1.56)
  [@bib15]                                             Pbo=1.04                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Pbo                                                  154                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  CAPTIVATE[⁎](#tblt0005-fn3){ref-type="table-fn"}     Pact 100                                                      443                                       55               39               hFH, LDL-C \>100 mg/dL (\>2.6 mmol/l); max cIMT\>0.7 -≤2.5 mm                                                             Statin Rx, 〈or〉 24 mon                                                   1                2004--2005                        Pac=0.785 Pbo=0.775           Pac=0.937 Pbo=0.927             140 (3.63)   52 (1.35)     130 (1.47)
  [@bib16]                                             **Pbo**                                                       438                                                                                                                                                                                                                                                                                                                                                                                                                          
  CASHMERE[⁎](#tblt0005-fn3){ref-type="table-fn"}      **A80**                                                       192                                       57               100              Postmenopause women ≤70 yr; LDL-C 130--190 mg/dL (3.36--4.86 mmol/l)                                                      No statins \>3 mon w/in last yr, or no LLT w/in last 6 wks                 1                2003--2006                        *A*=0.699                     NA                              159 (4.12)   66.6 (1.72)   120 (1.36)
  [@bib17]                                             Pbo                                                           206                                                        Pbo=0.683                                                                                                                                                                                                                                                                                                                                                         
  KAPS[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}         **P40**                                                       212                                       57               0                LDL-C 164 mg/dL (≥4.25 mmol/l), BMI ≤32 kg/m^2^                                                                           No prior LLT                                                               3                1989--1990                        1.35 (overall)                NA                              189 (4.90)   46 (1.19)     150 (1.70)
  [@bib18]                                             Pbo                                                           212                                                                                                                                                                                                                                                                                                                                                                                                                          
  LIPID[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}        **P40**                                                       273                                       61               12               MI or hospitalization for unstable angina[†](#tblt0005-fn4){ref-type="table-fn"}                                          2 mon run-in diet, no prior LLT                                            4                1990--1992                        *P*=0.804 Pbo=0.786           NA                              154 (3.99)   34.7 (0.90)   151 (1.71)
  [@bib13]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Pbo                                                  249                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  METEOR[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}       **R40**                                                       702                                       61               12               Asympotmatic, moderately elevated cholesterol with low CVD risk per ATPIII[‡](#tblt0005-fn5){ref-type="table-fn"}         No LLT 12 mon prior                                                        2                2002--2004                        *R*=0.76                      *R*=1.15 Pbo=1.17               165 (4.27)   50 (1.30)     130 (1.47)
  Pbo=0.76                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  [@bib7]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Pbo                                                  282                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  PLAC II[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}      **P20→40**[a](#tblt0005-fn6){ref-type="table-fn"}             75                                        61               12               CAD, LDL-C 60--90th percentile, ≥1 IMT lesion ≥1.3 mm                                                                     No prior LLT                                                               3                1988--1990                        *P*=1.01                      *P*=1.32 Pbo=1.32               166 (4.30)   41 (1.06)     171 (1.93)
  [@bib6]                                              Pbo=1.01                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Pbo                                                  76                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  RADIANCE I[⁎](#tblt0005-fn3){ref-type="table-fn"}    **A10, 20, 40, 80** A+T60                                     454                                       61               12               hFH                                                                                                                       Aspirin 30%; beta blocker 20%; ACE inh or ARB 16--19%; E 21%               2                2003--2004                        *A*=0.72 *A*+*T*=0.71         *A*=1.15 *A*+*T*=1.09           139 (3.60)   53 (1.37)     97 (1.10)
  [@bib11]                                             450                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  RADIANCE II[⁎](#tblt0005-fn3){ref-type="table-fn"}   **A10, 20, 40, 80** A+T60                                     375                                       57               37               Mixed HL eligible for statin Rx by ATPIII; max IMT=1.2--3.5 mm HDL-C ≤1.6 mmol/l[§](#tblt0005-fn7){ref-type="table-fn"}   Aspirin 55%, beta blocker 24--29%; ACE inh or ARB 37--39%; no LLT ≥4 wks   2                2003--2006                        *A*=0.83 *A*+*T*=0.83         *A*=1.3 *A*+*T*=1.32            101 (2.62)   48 (1.24)     167 (1.89)
  [@bib5]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  377                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  REGRESS[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}      **P40**                                                       131                                       56               0                CAD, symptomatic, coronary angiogram ≥50% reduction in ≥1 major coronary artery[¶](#tblt0005-fn8){ref-type="table-fn"}    No LLT ≤6 wks (≤12 wks for fibrates)                                       2                1989--1991                        *P*=0.87 Pbo=0.86             *P*=1.08                        168 (4.35)   38 (0.98)     163 (1.84)
  Pbo=1.07                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  [@bib8]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Pbo                                                  124                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  **Studies with statin arms**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ENHANCE[⁎](#tblt0005-fn3){ref-type="table-fn"}       **S80**                                                       342                                       46               51               hFH                                                                                                                       Untreated, LDL-C \>210 mg/dL 5.44 mmol/l), 81% prior statin use            2                2002--2006                        *S*=0.68 *S*+*E*=0.68         *S*=0.8 *S*+*E*=0.8             319 (8.26)   47 (1.22)     159 (1.80)
  [@bib12]                                             S80+E10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  338                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  VYCTOR[⁎⁎](#tblt0005-fn2){ref-type="table-fn"}       **P40**                                                       ≥18                                       58               57               10 yr absolute risk for CHD or MI ≥20 per ATPIII                                                                          Low dose statins, none received E previously                               1                2005                              NA                            *P*=1.33 *S*=1.3 *S*+*E*=1.23   130 (3.37)   45.3 (1.17)   192 (2.17)
  [@bib14]                                             **S40**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  S20+E10[b](#tblt0005-fn9){ref-type="table-fn"}       ≥18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ≥18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ARBITER II[⁎](#tblt0005-fn3){ref-type="table-fn"}    ERN 1000                                                      87                                        67               9                Known CVD, LDL-C \<130 mg/dL(\<3.37 mmol/l) and HDL-C \<45 mg/dL(\<1.17 mmol/l)                                           All patients on statins (93% S)                                            1                2001--2003                        ERN=0.89 Pbo=0.87             NA                              89 (2.31)    40 (1.04)     163 (1.84)
  [@bib21]                                             **Pbo**                                                       80                                                                                                                                                                                                                                                                                                                                                                                                                           

A=atorvastatin; ACE=angiotensin-converting enzyme; ARB=angiotensin-receptor blocker; CAD=coronary artery disease; CHD=coronary heart disease; CVD=cardiovascular disease;E=ezetimibe; hFH= heterozygous familial hypercholesterolemia L=lovastatin; Met=metropolo; P=pravastatin; Pac=pactimibe; Pbo=placebo; S=simvastatin; R=rosuvastatin; T=torcetrapib, W= warfarin.

Bold text denotes treatment arm in analysis.

Study was statistically significant (*p*\<0.05) for primary endpoint.

Study was non-significant (*p*\>0.05) for primary endpoint.

MI or hospitalization for unstable angina 3 mon--5 yr before enrollment and a total serum cholesterol 4--7 mmol/L (155--271 mg/dL) after 2 mon on low-fat diet; 88% men, 75% infarction, 5% diabetics.

LDL-C 120--190 mg/dL (3.10--4.92 mmol/l) w/0--1 CHD risk factors or 120--160 mg/dL (3.10--4.14 mmol/l) w/≥2 CHD risk factors and 10 yr risk \<10%, HDL-C ≤60 mg/dL (1.55 mmol/l); max IMT=1.2--3.5 mm.

LDL-C ≤160 - \>220 mg/dL (4.1 mmol/L) w/10 yr CHD risk \<10%; LDL‑C ≥130 -\<190mg/dL (3.37--4.92 mmol/L) w/10 yr CHD risk ≥10% and ≤20%, LDL‑C ≥115 -\<190 mg/dL (2.98--4.92 mmol/L) w/10 yr CHD risk \>20%, and TG ≥150 - ≤500 mg/dL (1.70--5.65 mmol/L).

Cholesterol 155--310 mg/dl (4.01--8.03 mmol/l).

P20 initially, change to 40 mg based on LDL-C.

S20+E10 initially, change to S40+E based on LDL-C.

###### 

Pooled baseline mean maximum CCA/cIMT and annualized rates of change[\*](#tbl2fna2){ref-type="table-fn"}.

Table 2

                                                                   **Studies**   **Patients**   **Baseline mean max CCA/cIMT \[mm\]**[†](#tbl2fnb3){ref-type="table-fn"}   **Annualized change mean max CCA/cIMT \[mm/yr\]**[†](#tbl2fnb3){ref-type="table-fn"}[‡](#tblt0010-fn4){ref-type="table-fn"}   
  ---------------------------------------------------------------- ------------- -------------- -------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- --------------------
   Overall                                                         12            5051           1.0866 (0.0032)                                                            −0.0023 (0.0014)                                                                                                              (−0.0050, −0.0004)
   Study year[§](#tbl2fnd5){ref-type="table-fn"}                                                                                                                                                                                                                                                         
    Before 2000                                                    5             1955           1.2550 (0.0059)                                                            −0.0134 (0.0020)                                                                                                              (−0.0173, −0.0096)
    After 2000                                                     7             3096           1.0181 (0.0038)                                                            0.0083 (0.0019)                                                                                                               (−0.0046, 0.0121)
   CHD risk                                                                                                                                                                                                                                                                                              
    Yes                                                            4             1242           1.3022 (0.0071)                                                            0.0021 (0.0030)                                                                                                               (−0.0038, 0.0081)
    No                                                             8             3809           1.0317 (0.0036)                                                            −0.0034 (0.0015)                                                                                                              (−0.0065, −0.0004)
   hFH                                                                                                                                                                                                                                                                                                   
    Yes                                                            3             1677           0.9130 (0.0050)                                                            0.0053 (0.0024)                                                                                                               (0.0005, 0.0100)
    No                                                             9             3374           1.2032 (0.0041)                                                            −0.0059 (0.0017)                                                                                                              (−0.0091, −0.0026)
   Thickened baseline IMT[¶](#tblt0010-fn6){ref-type="table-fn"}                                                                                                                                                                                                                                         
    Yes                                                            3             1964           1.1703 (0.0052)                                                            −0.0135 (0.0020)                                                                                                              (−0.0175, −0.0095)
    No                                                             9             3087           1.0375 (0.0040)                                                            0.0074 (0.0019)                                                                                                               (−0.0037, 0.0111)
   LDL-C reduction                                                                                                                                                                                                                                                                                       
    \<−27.6%                                                       6             3259           1.1335 (0.0042)                                                            −0.0036 (0.0016)                                                                                                              (−0.0066, −0.0005)
    ≥−27.6%                                                        6             1792           1.0200 (0.0050)                                                            0.0025 (0.0030)                                                                                                               (−0.0034, −0.0083)
   Mean age (yr)                                                                                                                                                                                                                                                                                         
    \<57                                                           5             2237           0.9454 (0.0044)                                                            −0.0045 (0.0017)                                                                                                              (−0.0077, −0.0012)
    ≥57                                                            7             2814           1.2423 (0.0046)                                                            0.0023 (0.0024)                                                                                                               (−0.0024, 0.0071)
   Female (%)                                                                                                                                                                                                                                                                                            
    \<40                                                           5             1800           0.9853 (0.0058)                                                            0.0204 (0.0043)                                                                                                               (0.0119, 0.0289)
    ≥40                                                            7             3251           1.1299 (0.0038)                                                            −0.0048 (0.0015)                                                                                                              (−0.0077, −0.0020)

hFH=heterozygous familial hypercholesterolemia.

Studies included: ACAPS, ARBITER I, BCAPS, CAIUS, CAPTIVATE, ENHANCE simvastatin, REGRESS, METEOR, PLAC II, VYCTOR, and RADIANCE I & II (atorvastatin arms). The PLAC II study was excluded from the baseline analysis because of missing baseline standard error information.

Pooled estimates for subgroups are weighted based on the inverse of the square of the standard error for the individual studies.

SE and 95%CI are based on study-end values for the treatment difference (placebo-controlled) or change from baseline (monotherapy arms) in cIMT.

Studies conducted before 2000: ACAPS, BCAPS, CAIUS, PLAC II, REGRESS. Studies conducted after 2000: ARBITER I, CAPTIVATE, ENHANCE, METEOR, VYCTOR, and RADIANCE I & II (atorvastatinarms)..

Entry criteria.

###### 

Pooled baseline mean mean CCA/cIMT and annualized rates of change in studies before and after 2000 for subgroups.

Table 3

                                                                **Studies before 2000**[⁎](#tbl3fna1){ref-type="table-fn"}   **Studies after 2000**[⁎⁎](#tbl3fnb2){ref-type="table-fn"}                                                                                                             
  ------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ ----------------- ------------------ -------------------- --- ------ ----------------- ------------------ --------------------
   CHD risk                                                                                                                                                                                                                                                                                         
    Yes                                                         3                                                            1201                                                         0.8008 (0.0064)   −0.0184 (0.0051)   (−0.0283, −0.0084)   1   375    0.8300 (0.0072)   0.0080 (0.0020)    (0.0041, 0.0119)
    No                                                          2                                                            1064                                                         0.8898 (0.0054)   −0.0098 (0.0029)   (−0.0155, −0.0042)   7   3131   0.7367 (0.0024)   −0.0033 (0.0009)   (−0.0051, −0.0015)
   hFH                                                                                                                                                                                                                                                                                              
    Yes                                                         1                                                            281                                                          0.8645 (0.0094)   −0.0138 (0.0069)   (−0.0273, −0.0003)   3   1677   0.7435 (0.0036)   −0.0005 (0.0012)   (−0.0113, −0.0057)
    No                                                          4                                                            1984                                                         0.8492 (0.0046)   −0.0117 (0.0027)   (−0.0170, −0.0064)   5   1829   0.7473 (0.0029)   −0.0021 (0.0012)   (0.0003, 0.0043)
   Thickened baseline cIMT[§](#tbl3fnc5){ref-type="table-fn"}                                                                                                                                                                                                                                       
    Yes                                                         1                                                            783                                                          0.9026 (0.0067)   −0.0090 (0.0032)   (−0.0153, −0.0027)   4   1781   0.7782 (0.0036)   −0.0085 (0.0015)   (−0.0113, −0.0057)
    No                                                          4                                                            1482                                                         0.8207 (0.0053)   −0.0167 (0.0041)   (−0.0247, −0.0087)   4   1725   0.7242 (0.0029)   0.0023 (0.0010)    (0.0003, 0.0043)
   LDL-C reduction (median)                                                                                                                                                                                                                                                                         
    \<−27.6%                                                    2                                                            1305                                                         0.8484 (0.0047)   −0.0096 (0.0030)   (−0.0156, −0.0036)   4   1781   0.7782 (0.0036)   0.0021 (0.0011)    (0.0000, 0.0042)
    ≥−27.6%                                                     3                                                            960                                                          0.8645 (0.0086)   −0.0170 (0.0045)   (−0.0258, −0.0082)   4   1725   0.7242 (0.0029)   −0.0066 (0.0013)   (−0.0092, −0.0040)
   Mean age (yr)                                                                                                                                                                                                                                                                                    
    \<57                                                        2                                                            536                                                          0.8645 (0.0086)   −0.0148 (0.0066)   (−0.0277, −0.0019)   3   1677   0.7435 (0.0036)   −0.0005 (0.0012)   (−0.0028, 0.0019)
    ≥57                                                         3                                                            1729                                                         0.8484 (0.0047)   −0.0115 (0.0027)   (−0.0168, −0.0061)   5   1829   0.7473 (0.0029)   −0.0021 (0.0012)   (−0.0043, 0.0002)
   Female (%)                                                                                                                                                                                                                                                                                       
    \<40                                                        3                                                            1201                                                         0.8008 (0.0064)   −0.0184 (0.0051)   (−0.0283, −0.0084)   4   1465   0.7835 (0.0040)   0.0094 (0.0019)    (0.0057, 0.0130)
    ≥40                                                         2                                                            1064                                                         0.8898 (0.0054)   −0.0098 (0.0029)   (−0.0155, −0.0042)   4   2041   0.7277 (0.0027)   −0.0040 (0.0009)   (−0.0058, −0.0021)

hFH=heterozygous familial hypercholesterolemia; CHD=coronary heart disease; IMT=statins.

Studies before 2000 included REGRESS, ASAP, LIPID, and BCAPS, KAPS study was excluded from the baseline analysis due to missing baseline standard error information.

Studies after 2000 included ARBITER I, METEOR, CASHMERE, CAPTIVATE, ENHANCE (simvastatin arm), ARBITER II (placebo arm), and Radiance I & II (atorvastatin arm).

Pooled estimates for subgroups are weighted based on the inverse of the square of the standard error for the individual studies.

SE and 95%CI are based on study-end values for the treatment difference (placebo-controlled) or change from baseline (monotherapy arms) in cIMT.

Entry criteria.

###### 

Pooled baseline mean maximum CCA/cIMT and annualized rates of change in studies before and after 2000[\*](#tbl4fna1){ref-type="table-fn"} for subgroups.

Table 4

                                                                **Studies before 2000**[\*](#tbl4fna1){ref-type="table-fn"}   **Studies after 2000**[⁎⁎](#tbl4fnb2){ref-type="table-fn"}                                                                                                             
  ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------ ----------------- ------------------ -------------------- --- ------ ----------------- ------------------ --------------------
   CHD risk                                                                                                                                                                                                                                                                                          
    Yes                                                         3                                                             867                                                          1.3028 (0.0080)   −0.0140 (0.0038)   (−0.0215, −0.0066)   1   375    1.3000 (0.0150)   0.0300 (0.0050)    (0.0202, 0.0398)
    No                                                          2                                                             1088                                                         1.1975 (0.0088)   −0.0132 (0.0023)   (−0.0177, −0.0087)   6   2721   0.9989 (0.0039)   0.0046 (0.0021)    (0.0005, 0.0087)
   hFH                                                                                                                                                                                                                                                                                               
    Yes                                                         0                                                             0                                                            --                --                 --                   3   1677   0.9130 (0.0050)   0.0053 (0.0024)    (0.0005, 0.0100)
    No                                                          5                                                             1955                                                         1.2550 (0.0059)   −0.0134 (0.0020)   (−0.0173, −0.0096)   4   1419   1.1547 (0.0057)   0.0135 (0.0032)    (0.0074, 0.0197)
   Thickened baseline cIMT[§](#tbl4fnc5){ref-type="table-fn"}                                                                                                                                                                                                                                        
    Yes                                                         2                                                             1088                                                         1.1975 (0.0088)   −0.0132 (0.0023)   (−0.0177, −0.0087)   1   876    1.1553 (0.0065)   −0.0145 (0.0042)   (−0.0228, −0.0062)
    No                                                          3                                                             867                                                          1.3028 (0.0080)   −0.0140 (0.0038)   (−0.0215, −0.0066)   6   2220   0.9486 (0.0046)   0.0143 (0.0022)    (0.0101, 0.0186)
   LDL-C reduction (median)                                                                                                                                                                                                                                                                          
    \<−27.6%                                                    3                                                             1549                                                         1.2642 (0.0061)   −0.0136 (0.0020)   (0.0176, −0.0097)    3   1710   1.0180 (0.0057)   0.0112 (0.0024)    (0.0064, 0.0160)
    ≥−27.6%                                                     2                                                             406                                                          1.0747 (0.0269)   −0.0088 (0.0095)   (−0.0275, 0.0099)    4   1386   1.0181 (0.0050)   0.0037 (0.0031)    (−0.0025, 0.0098)
   Mean age (yr)                                                                                                                                                                                                                                                                                     
    \<57                                                        2                                                             560                                                          1.0515 (0.0091)   −0.0132 (0.0023)   (−0.0177, −0.0087)   3   1677   0.9130 (0.0050)   0.0053 (0.0024)    (0.0005, 0.0100)
    ≥57                                                         3                                                             1395                                                         1.4045 (0.0078)   −0.0139 (0.0038)   (−0.0214, −0.0065)   4   1419   1.1547 (0.0057)   0.0135 (0.0031)    (0.0074, 0.0197)
   Female (%)                                                                                                                                                                                                                                                                                        
   \<40                                                         2                                                             406                                                          1.0747 (0.0269)   −0.0088 (0.0095)   (−0.0275, 0.0099)    3   1394   0.9809 (0.0060)   0.0280 (0.0049)    (0.0185, 0.0375)
   ≥40                                                          3                                                             1549                                                         1.2642 (0.0061)   −0.0136 (0.0020)   (−0.0176, −0.0097)   4   1702   1.0430 (0.0049)   0.0047 (0.0021)    (0.0006, 0.0088)

hFH=heterozygous familial hypercholesterolemia; CHD=coronary heart disease; cIMT=carotid intima media thickness.

Studies conducted before 2000: ACAPS, BCAPS, CAIUS, PLAC II, REGRESS.

Studies conducted after 2000: ARBITER I, CAPTIVATE, ENHANCE, METEOR, VYCTOR, and RADIANCE I & II (atorvastatin arms).

Pooled estimates for subgroups are weighted based on the inverse of the square of the standard error for the individual studies.

SE and 95%CI are based on study-end values for the treatment difference (placebo-controlled) or change from baseline (monotherapy arms) in cIMT.

Entry criteria.
